An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in France

Clinical Trial ID NCT02979769

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02979769

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med 2011 2.40
Next 100